Dublin, May 12, 2021 (GLOBE NEWSWIRE) -- The "Global Inflammatory Bowel Disease (IBD) Market - Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
The Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020, has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn's Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression.
Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol consumption and cigarette smoking are likely to contribute towards the growth of the IBD market.
Additionally, rise in investments in building a robust pipeline for IBD, increase in lifestyle-related risk factors and growing popularity of prebiotic and probiotic foods are likely to boost the growth of the global market during the forecast period.
The North America region dominates the market. In North America, rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in United States and significant funding in the IBD field in Canada is further estimated to boost the growth of the IBD market in the region.
The IBD market in North America has remained at the forefront in terms of growth opportunities as well as developments in the field of Crohn's Disease over the years. The region is likely to continue to account for a significant piece of the revenue pie over the next few years as well, thanks to the presence of several pharmaceutical and biosciences companies and the presence of numerous leading players in the field of Crohn's Disease.
Additionally, increasing geriatric population base and prevalence of Ulcerative Colitis and Crohn's disease and also well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across regions would enhance the growth of the market during the forecast period.
Key Topics Covered:
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Global Inflammatory Bowel Disease Market: Product Outlook
4. Global Inflammatory Bowel Disease Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Inflammatory Bowel Disease Market
5. Global Inflammatory Bowel Disease Market Segmentation By Disease Indication (By Value)
5.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Disease Indication
5.2 Crohn's Disease - Market Size and Forecast (2016-2026)
5.3 Ulcerative Colitis - Market Size and Forecast (2016-2026)
6. Global Inflammatory Bowel Disease Market Segmentation By Drug Class (By Value)
6.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Drug Class
6.2 TNF Inhibitors - Market Size and Forecast (2016-2026)
6.3 Aminosalicylates - Market Size and Forecast (2016-2026)
6.4 Integrin Antagonists - Market Size and Forecast (2016-2026)
6.5 Others - Market Size and Forecast (2016-2026)
7. Global Inflammatory Bowel Disease Market Segmentation By Distribution Channel (By Value)
7.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Distribution Channel
7.2 Hospital Pharmacies - Market Size and Forecast (2016-2026)
7.3 Retail Pharmacies - Market Size and Forecast (2016-2026)
7.4 Online Pharmacies - Market Size and Forecast (2016-2026)
8. Global Inflammatory Bowel Disease Market: Regional Analysis
8.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Region
9. North America Inflammatory Bowel Disease Market: An Analysis (2016-2026)
9.1 North America Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.2 North America Inflammatory Bowel Disease Market - Prominent Companies
9.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative Colitis.)
9.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists and Others.)
9.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)
9.6 North America Inflammatory Bowel Disease Market: Country Analysis
9.7 Market Opportunity Chart of North America Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
9.8 Competitive Scenario of North America - By Country
9.9 United States Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.10 United States Inflammatory Bowel Disease Market Leading Companies
9.11 United States Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
9.12 Canada Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.13 Canada Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class and Distribution Channel.
10. Europe Inflammatory Bowel Disease Market: An Analysis (2016-2026)
11. Asia Pacific Inflammatory Bowel Disease Market: An Analysis (2016-2026)
12. Global Inflammatory Bowel Disease Market Dynamics
12.1 Global Inflammatory Bowel Disease Market Drivers
12.2 Global Inflammatory Bowel Disease Market Restraints
12.3 Global Inflammatory Bowel Disease Market Trends
13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.2 Strategic Analysis
13.2.1 Mergers and Acquisitions
13.2.2 Recent Industry Developments
14. Competitive Landscape
14.1 Market Share Analysis
15. Inflammatory Bowel Disease Pipeline Development
15.1 Emerging Therapies in Inflammatory Bowel Disease
16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Johnson & Johnson
16.2 AbbVie Inc.
16.3 Takeda
16.4 Pfizer
16.5 Roche
16.6 Celgene
16.7 GlaxoSmithKline
16.8 Novartis
16.9 UCB
16.10 Eli Lilly & Company
For more information about this report visit https://www.researchandmarkets.com/r/hx8b5i